4/17/2021 1:50:34 PM
Amarin Presents Further Analyses Of Icosapent Ethyl On Progression Of Coronary Atherosclerosis In EVAPORATE Trial
3/30/2021 6:39:46 AM
Amarin Says European Commission Approved Marketing Authorization Application For VAZKEPA
1/28/2021 6:42:55 AM
VASCEPA Gets Inclusions In Guidelines From Int'l Medical Societies For Role In Reducing Risk Of Cardiovascular Events
1/25/2021 7:46:00 PM
Amarin Expands Cardiovascular Risk Reduction Patent Infringement Lawsuit To Include Health Care Insurance Provider
1/7/2021 6:07:00 AM
Amarin Sees 2020 Total Net Revenue To Be About $610 Mln
12/13/2020 9:51:40 AM
Amarin Presents Encouraging Efficacy & Safety Results From Pilot Study Treating COVID-19 Infected Patients With VASCEPA
11/30/2020 8:26:11 PM
Amarin Files Patent Infringement Lawsuit Against Hikma
8/4/2020 6:37:32 AM
Amarin Plans To Undertake Its Own Focused Commercial Launch Of VASCEPA In Europe
6/15/2020 7:17:51 AM
Amarin Presents Data From The REDUCE-IT Study
6/1/2020 7:16:34 AM
Amarin To Increase Level And Breadth Of Promotion And Education Initiatives Regarding VASCEPA